Nearly 50% of blood cancer patients insufficiently protected against Omicron after three jabs, study says

Findings support need for a fourth jab among these vulnerable people, say scientists

Samuel Lovett
Science Correspondent
Tuesday 25 January 2022 23:50
Comments
<p>Among patients with blood cancer who had three doses of a Covid-19 vaccine, only 56 per cent generated neutralising antibodies</p>

Among patients with blood cancer who had three doses of a Covid-19 vaccine, only 56 per cent generated neutralising antibodies

Nearly half of patients with blood cancer are insufficiently protected against the Omicron variant after three vaccine doses, according to a new study.

Experts from the Francis Crick Institute and the Royal Marsden NHS Foundation Trust said their research highlights the need for a fourth jab among these vulnerable people.

As part of the ongoing Capture study, scientists have been monitoring the antibody response of hundreds of patients with different types of cancer, after one, two and three vaccine doses.

Specifically, the researchers measured levels of neutralising antibodies which identify, attack and block the Omicron variant from infecting the body’s cells.

Patients with solid tumours appeared to generate antibody responses similar to people without cancer.

But among patients with blood cancer who had three doses of a Covid-19 vaccine, only 56 per cent generated neutralising antibodies, according to the study, which has been published as a research letter in The Lancet.

This means that 44 per cent of patients with blood cancer did not generate a sufficient antibody response.

The researchers highlight that antibodies are not the only line of defence in the body and patients may also have protection from other parts of the immune system.

But they said that the study supports the need for four jabs among these immunocompromised groups of people.

“We found that a third vaccine dose boosted the neutralising response against Omicron in patients with cancer, but the effect was blunted in patients with blood cancer compared to those with solid cancer,” the authors wrote.

They said that their study supports the UK policy of offering a fourth jab to some patients.

In the UK, people with severe immunosuppression aged 12 and over are offered three Covid-19 jabs as an initial course of vaccination. They are then offered a fourth booster.

Dr Samra Turajlic, lead author and group leader at the Crick and consultant medical oncologist at The Royal Marsden, said: “The pandemic has been especially difficult for people living with cancer and up-to-date information about immunity levels are particularly important for this vulnerable group.

“We now know that the immune response to vaccines in patients with solid cancers are robust after three doses as compared to people without cancer, even against the new Omicron variant.

“But for people with blood cancers, Omicron poses a greater risk.

“These patients should remain cautious and come forward for their fourth booster dose as soon as it’s available to them.

“Protecting this vulnerable group is important, especially in the light of the recent easing of Covid-19 restrictions in the UK such as ending mandates requiring people to wear a face mask.

“Public health measures must be inclusive and supportive of everyone, including vulnerable people and their carers.”

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Please enter a valid email
Please enter a valid email
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Please enter your first name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
Please enter your last name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
You must be over 18 years old to register
You must be over 18 years old to register
Opt-out-policy
You can opt-out at any time by signing in to your account to manage your preferences. Each email has a link to unsubscribe.

By clicking ‘Create my account’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Join our new commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in